Wikisage, the free encyclopedia of the second generation, is digital heritage

Rufinamide: Difference between revisions

From Wikisage
Jump to navigation Jump to search
m (hide url)
No edit summary
 
(11 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Lennox-Gastaut syndrome|Lennox-Gastaut]] is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside
[[Lennox-Gastaut syndrome|Lennox-Gastaut]] is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive.
Otsuka et al (2014) state efficacious and well tolerated AED
Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated [[Antiepileptic drug|AED]]
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>(cf. Alssad et Coren 2014) <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256616/pdf/bcp0078-1264.pdf Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials] </ref>
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref>(cf. Alssad et Coren 2014) <ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256616/pdf/bcp0078-1264.pdf Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials] </ref>
<gallery>File:Under construction icon.png</gallery>
<small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small>
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf  Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref>
It is an inductor of [[Cytochrome P450|CYP 450]]
==Weblinks==


[http://flexikon.doccheck.com/de/Rufinamid FLexikon:Rufinamid]


<small>"Rufinamide received the status of orphan drug for [[epilepsy]] in 2004 in Europe"</small>
[http://www.pharmawiki.ch/wiki/index.php?wiki=Rufinamid Pharmawiki:Rufinamid]
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf  Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]</ref>
==[[ATC]]==
 
<gallery>File:Rufinamid.svg.png</gallery>
https://www.whocc.no/atc_ddd_index/?code=N03AF03
 
{{refs}}


<references/>
{{Wikidata|Q408565}}
{{Wikidata|Q408565}}


[[Category:Anticonvulsants]]
[[Category:Anticonvulsants]]

Latest revision as of 20:41, 20 March 2023

Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive. Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]

"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]

It is an inductor of CYP 450

Weblinks

FLexikon:Rufinamid

Pharmawiki:Rufinamid

ATC

https://www.whocc.no/atc_ddd_index/?code=N03AF03

References

References:

Q408565 at Wikidata  Interwiki via Wikidata